Adventrx Pharmaceuticals Inc., of San Diego, elected Michael Goldberg and Mark Pykett to its board.
Aethlon Medical Inc., of La Jolla, Calif., appointed Pedro Cuatrecasas to its science advisory board.
Ambion Inc., of Austin, Texas, named John Dahler chief financial officer.
Amgen Inc., of Thousand Oaks, Calif., named David Scott senior vice president, general counsel, secretary and a member of its executive committee.
Aphton Corp., of Miami, appointed James Smith as an independent director. The company also appointed Patrick Mooney president, CEO and a director, and Doy Michaeli chief medical officer.
ARYx Therapeutics Inc., of Santa Clara, Calif., appointed John Varian chief operating officer, Donn Dennis vice president of pharmacology and David Nagler vice president of corporate affairs.
Atrix Laboratories Inc., of Fort Collins, Colo., appointed Stephen Warren chief scientific officer, in addition to his position as vice president of research and development.
Australian Cancer Technology, of Sydney, appointed Rick Phipps and Kerry O'Banion to its scientific advisory board.
Avalon Pharmaceuticals Inc., of Germantown, Md., hired James Meadeas vice president for business development and promoted Paul Young to vice president of research.